CN1772766A - 抗细胞凋亡相关乙酰胆碱酯酶单克隆抗体及其用途 - Google Patents
抗细胞凋亡相关乙酰胆碱酯酶单克隆抗体及其用途 Download PDFInfo
- Publication number
- CN1772766A CN1772766A CNA2004100681470A CN200410068147A CN1772766A CN 1772766 A CN1772766 A CN 1772766A CN A2004100681470 A CNA2004100681470 A CN A2004100681470A CN 200410068147 A CN200410068147 A CN 200410068147A CN 1772766 A CN1772766 A CN 1772766A
- Authority
- CN
- China
- Prior art keywords
- ache
- monoclonal antibody
- antibody
- cell
- apoptosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2510/00—Detection of programmed cell death, i.e. apoptosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2004100681470A CN1772766A (zh) | 2004-11-12 | 2004-11-12 | 抗细胞凋亡相关乙酰胆碱酯酶单克隆抗体及其用途 |
PCT/CN2005/001888 WO2006050667A1 (fr) | 2004-11-12 | 2005-11-10 | ANTICORPS MONOCLONAUX DIRIGES CONTRE L’ACETYLCHOLINESTERASE LIEE A L’APOPTOSE (AR-AChE) ET LEUR USAGE |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2004100681470A CN1772766A (zh) | 2004-11-12 | 2004-11-12 | 抗细胞凋亡相关乙酰胆碱酯酶单克隆抗体及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1772766A true CN1772766A (zh) | 2006-05-17 |
Family
ID=36336211
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2004100681470A Pending CN1772766A (zh) | 2004-11-12 | 2004-11-12 | 抗细胞凋亡相关乙酰胆碱酯酶单克隆抗体及其用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN1772766A (fr) |
WO (1) | WO2006050667A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102921000A (zh) * | 2011-08-08 | 2013-02-13 | 中国科学院上海生命科学研究院 | 乙酰胆碱酯酶作为核酸酶的应用 |
CN103087154A (zh) * | 2012-12-05 | 2013-05-08 | 江苏澳格姆生物科技有限公司 | 一种用于制备检测乙酰胆碱酯酶的单克隆抗体的多肽及其应用 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
PT1976877E (pt) | 2005-11-30 | 2014-04-29 | Abbvie Inc | Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações |
ES2524984T3 (es) | 2005-11-30 | 2014-12-16 | Abbvie Inc. | Anticuerpos anti-globulómero a?, porciones de unión a antígeno de estos, hibridomas correspondientes, ácidos nucleicos, vectores, células huésped, métodos para producir dichos anticuerpos, composiciones que comprenden dichos anticuerpos, usos de dichos anticuerpos, y métodos para usar dichos anticuerpos |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
MX336196B (es) | 2010-04-15 | 2016-01-11 | Abbvie Inc | Proteinas de union a amiloide beta. |
EP3533803B1 (fr) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anticorps anti-bêta-amyloïde |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8927389D0 (en) * | 1989-12-04 | 1990-01-31 | Jehanli Ahmed M T | Monoclonal antibodies |
GB9606040D0 (en) * | 1996-03-22 | 1996-05-22 | Isis Innovation | Active peptide |
CN1072722C (zh) * | 1997-12-30 | 2001-10-10 | 中国科学院上海细胞生物学研究所 | 抗肿瘤药物的筛选方法 |
CN1059702C (zh) * | 1997-12-30 | 2000-12-20 | 中国科学院上海细胞生物学研究所 | 从哺乳类细胞中获得脑型乙酰胆碱酯酶的方法 |
IL140071A0 (en) * | 2000-12-04 | 2002-02-10 | Yissum Res Dev Co | Human antibodies to specific acetylcholinesterase variants and their use as diagnostic agents for cholinergic neurodeterioration processes |
CN1244700C (zh) * | 2001-03-23 | 2006-03-08 | 中国科学院上海细胞生物学研究所 | 一种人乙酰胆碱酯酶异构体蛋白(ar-ache)及基因编码序列 |
-
2004
- 2004-11-12 CN CNA2004100681470A patent/CN1772766A/zh active Pending
-
2005
- 2005-11-10 WO PCT/CN2005/001888 patent/WO2006050667A1/fr active Application Filing
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102921000A (zh) * | 2011-08-08 | 2013-02-13 | 中国科学院上海生命科学研究院 | 乙酰胆碱酯酶作为核酸酶的应用 |
CN102921000B (zh) * | 2011-08-08 | 2015-02-18 | 中国科学院上海生命科学研究院 | 乙酰胆碱酯酶作为核酸酶的应用 |
CN103087154A (zh) * | 2012-12-05 | 2013-05-08 | 江苏澳格姆生物科技有限公司 | 一种用于制备检测乙酰胆碱酯酶的单克隆抗体的多肽及其应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2006050667A1 (fr) | 2006-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101080421A (zh) | 抗体以及其利用 | |
CN1244921A (zh) | 癌症的治疗和诊断 | |
CN1345331A (zh) | 抑制血管发生的组合物和方法 | |
CN102918059A (zh) | 抗cd27抗体 | |
CN1133886A (zh) | 得到经过修饰降低了鼠抗体可变区之免疫原性的免疫球蛋白的方法及含有免疫球蛋白的组合物 | |
CN1285754A (zh) | 单克隆人天然抗体 | |
CN1578838A (zh) | 生产具有预定的翻译后修饰的蛋白质的方法和手段 | |
UA117446C2 (uk) | Гуманізоване антитіло до cxcr5 | |
CN1069522A (zh) | 细胞间粘附分子-3及其配体 | |
CN1630663A (zh) | 结合蛋白磷酸酶2a的合成的或者天然的肽,其鉴定方法以及用途 | |
CN101054417A (zh) | 神经节苷脂相关的重组抗体及其在肿瘤的诊断和治疗中的应用 | |
UA120264C2 (uk) | Сполука для застосування в способі лікування імунодефіциту сd4-т клітин у суб'єкта | |
CN1907953A (zh) | 一种用于氯胺酮检测的单克隆抗体及免疫检测板 | |
CN1682111A (zh) | 诊断致瘤力以及确定对抗癌疗法的抗性 | |
CN1772766A (zh) | 抗细胞凋亡相关乙酰胆碱酯酶单克隆抗体及其用途 | |
CN1357046A (zh) | 几丁质酶几丁质-结合片段 | |
CN1284134A (zh) | 利用毕赤氏酵母表达系统生产抗生血管蛋白质∶制管张素,内抑制素或静息蛋白的方法 | |
CN101074264A (zh) | 一种重组抗ctla4单克隆抗体及其制备方法和用途 | |
CN110177810A (zh) | 抗pcsk9抗体及其用途 | |
WO2022093640A1 (fr) | Agents anti-nkg2c et compositions et méthodes de production et d'utilisation de ceux-ci | |
CN1056186C (zh) | 一种对人体过氧化锰歧化酶的单克隆抗体,其制备方法及其应用 | |
CN1732261A (zh) | 用于诊断肝脏疾病的标志蛋白质以及使用该蛋白质诊断肝脏疾病的方法 | |
CN1418225A (zh) | 人低密度脂蛋白受体的单克隆抗体及其制备和用途 | |
CN1328567A (zh) | 乳房珠蛋白,一种分泌性乳房特异性乳腺癌蛋白 | |
CN1379685A (zh) | 用基于MMP-9和β1整联蛋白的拮抗剂抑制血管发生的新方法和组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20060517 |